Beate Sable
Amgen (United States)(US)
Publications by Year
Research Areas
Lung Cancer Research Studies, Neuroendocrine Tumor Research Advances, CAR-T cell therapy research, Cancer therapeutics and mechanisms, Peptidase Inhibition and Analysis
Most-Cited Works
- → Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (CAR‐T) Cell Therapy Targeting Delta‐Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC)(2023)34 cited
- → Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma(2018)26 cited
- → Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms(2024)17 cited
- → Abstract 5202: AMG 794, a Claudin 6-targeted half-life extended (HLE) bispecific T cell engager (BITE®) molecule for non-small cell lung cancer and epithelial ovarian cancer(2022)6 cited
- → OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC(2021)5 cited
- → Heterogeneity of canonical prostate cancer markers across lesions in metastatic castration-resistant prostate cancer.(2023)1 cited
- → 48MO Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)(2021)1 cited
- → Megakaryocytes Do Not Express Erythropoietin Receptor (EpoR) and Do Not Respond to Recombinant Human Erythropoietin (rHuEpo) Stimulation(2011)
- → Abstract 5305: Delta-like ligand 3 immunohistochemical expression landscape in high-grade lung neuroendocrine tumors(2022)